Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience

被引：0

作者：

Soini, Barbara

Pani, Giuseppe

Caffo, Orazio

Frisinghelli, Michela

Veccia, Antonello

Brugnara, Sonia

Caldara, Alessia

DiPasquale, MariaChiara

Ferro, Antonella

Mussari, Salvatore

Murgia, Viviana

Russo, Lucianna

Valduga, Francesco

Tumulo, Salvatore

Galligioni, Enzo

机构：

[1] Med Oncol Santa Chiara Hosp, Trento, Italy

[2] Radiotherapy Santa Chiara Hosp, Trento, Italy

[3] Santa Maria degli Angeli Hosp, Pordenone, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14711

引用

页数：1

共 50 条

[21] Adjuvant chemoradiotherapy in advanced gastric cancer. Experience in 168 patients
Isa O, Nicolas
Russo N, Moises
Lopez, Hernan, V
[J]. REVISTA MEDICA DE CHILE, 2014, 142 (02) : 199 - 203
[22] Is Adjuvant Chemoradiotherapy Better than Perioperative Chemotherapy for Resectable Gastric Cancer?
Selleck, M. J.
Jabo, B.
Morgan, J. W.
Garberoglio, C. A.
Reeves, M. E.
Namm, J. P.
Solomon, N. L.
Lum, S. S.
Senthil, M.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S177 - S177
[23] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
Xu, Nong
Shen, Lin
Jiang, Haiping
Zheng, Yulong
Qian, Jiong
Mao, Chenyu
Zhou, Hui
Wang, Shuyan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[24] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
Hall, J.
Khela, K.
Bertwistle, D.
Xiao, H.
[J]. VALUE IN HEALTH, 2020, 23 : S482 - S483
[25] Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
Teng, L.
Xu, N.
Jiang, H.
Zheng, Y.
Qian, J.
Mao, C.
Zhou, H.
Wang, S.
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1759 - 1760
[26] A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).
Xu, Jianming
Liu, Rongrui
Ying, Jieer
Wu, Jun
Ye, Feng
Xu, Nong
Zhang, Yanqiao
Zhao, Rusen
Xiang, Xiaojun
Wang, Jianhong
Lin, Xiaoyan
Xu, Huiting
Gao, Shegan
Luo, Suxia
Guo, Baohong
Li, Xionghui
Su, Yangzhi
Wang, Qian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] CONCURRENT CHEMORADIOTHERAPY (CCTRT) WITH WEEKLY CISPLATIN (WCDDP) IN LOCALLY ADVANCED CERVICAL CANCER (LACC) PATIENTS (PTS): A MONOINSTITUTIONAL EXPERIENCE
Murgia, Viviana
Arcuri, Carmela
Caffo, Orazio
Vanoni, Valentina
Magri, Elena
Ambrosini, Gianni
Brugnara, Sonia
Caldara, Alessia
Ferro, Antonella
Frisinghelli, Michela
Soini, Barbara
Valduga, Francesco
Arisi, Emilio
Galligioni, Enzo
[J]. ANNALS OF ONCOLOGY, 2009, 20
[28] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN CANADA
Amadi, A.
Toor, K.
Keeney, E.
Thom, H.
Singh, P.
Kim, I
Mameri, E.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
[29] A COST-EFFECTIVENESS ANALYSIS (CEA) OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN FRANCE
Paul, C.
Massettti, M.
Cotte, F. E.
Moreau, R.
Kassahun, S.
Singh, P.
Kim, I
Gaudin, A. F.
Leleu, H.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S180 - S180
[30] Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
M. C. J. Anderegg
P. C. van der Sluis
J. P. Ruurda
S. S. Gisbertz
M. C. C. M. Hulshof
M. van Vulpen
N. Haj Mohammed
H. W. M. van Laarhoven
M. J. Wiezer
M. Los
M. I. van Berge Henegouwen
R. van Hillegersberg
[J]. Annals of Surgical Oncology, 2017, 24 : 2282 - 2290

← 1 2 3 4 5 →